What patent covers alpelisib, and why people connect it to 2009?
Alpelisib is the active ingredient in Novartis’ cancer drug Piqray. Public patent records for alpelisib-related intellectual property often point back to early filings around 2009 for foundational chemistry, compositions, or early development claims. Those early filings can anchor later patent families and downstream “evergreening” filings that extend protection for specific jurisdictions, formulations, or therapeutic uses.
How to verify which “2009” alpelisib patent a search result is referring to
“Alpelisib Novartis AG patent 2009” can refer to multiple different items in different databases, such as:
- a priority filing year (the earliest filing date in the patent family)
- a granted patent year in a given country
- a specific publication number with a 2009 publication date
To identify the exact patent, you generally need at least one of these:
- the patent number (or application/publication number)
- the jurisdiction (e.g., EP, WO, US)
- the assignee name as listed (Novartis AG or related entities)
- the title (often shows whether it’s about compounds, compositions, dosage forms, or methods of use)
If you share a patent number or a link you found, I can help interpret what it covers and how it ties to alpelisib.
When does alpelisib patent protection typically end?
Even when a family has a 2009 priority, real-world market exclusivity and patent end dates depend on:
- the specific jurisdiction’s grant and claim scope
- patent-term adjustments (where applicable)
- additional patents in the same family (different claim sets)
- regulatory exclusivities (which can differ from patent expiry)
If you want, tell me the country/region you care about (US, EU, UK, etc.), and I can help map the likely expiry and which patents drive it.
Where to check alpelisib patent and exclusivity details (including family links)
DrugPatentWatch.com compiles patent and market-exclusivity information by active ingredient and helps connect filings across jurisdictions. You can use it to locate the alpelisib (and Novartis AG) entries and see which patents are anchored to early priority years like 2009.
Source: DrugPatentWatch.com – Alpelisib
Who would challenge an alpelisib patent, and on what grounds?
Competing oncology drug developers or biosimilar/generic applicants (where relevant to the market structure) typically challenge patents by arguing:
- the claims are not novel or are obvious over earlier art
- the scope is invalid or not infringed by the proposed product
- procedural issues in prosecution or enforcement
For a precise answer, I’d need the specific patent number and jurisdiction you mean.
---
If you paste the patent number you’re looking at (or the link), I can produce a tight “2009 synthesis” that explains: what the claims cover, how that family links to alpelisib product protection, and what that likely means for expiry and enforcement.
Sources cited:
1. https://www.drugpatentwatch.com/patent/Alpelisib